GLUE

14.32

0.42% 0.06

Dopo l'orario di chiusura: 14.82 0.50 +3.49%

Monte Rosa Therapeutics Inc (GLUE)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché GLUE Giù? Forum Previsione

Precedente Chiudi:

$14.26

Aprire:

$14.21

Volume 24 ore:

1.06M

Relative Volume:

0.75

Capitalizzazione di mercato:

$1.22B

Reddito:

$42.95M

Utile/perdita netta:

$-130.01M

Rapporto P/E:

-8.7971

EPS:

-1.6278

Flusso di cassa netto:

$-19.66M

1 W Prestazione:

-0.42%

1M Prestazione:

-9.48%

6M Prestazione:

-17.13%

1 anno Prestazione:

+198.33%

Intervallo 1D:

$13.83

$14.34

Intervallo di 1 settimana:

$13.44

$14.87

Portata 52W:

$4.795

$25.77

Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile

Nome

Monte Rosa Therapeutics Inc

Settore

Healthcare (1069)

Industria

Biotechnology (595)

Telefono

617-949-2643

Indirizzo

321 HARRISON AVENUE, BOSTON

Dipendente

161

Cinguettio

Prossima data di guadagno

2026-08-06

Ultimi documenti SEC

GLUE's Discussions on Twitter

Compare GLUE vs VRTX, REGN, ARGX, MRNA, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
GLUE Monte Rosa Therapeutics Inc	14.32	1.22B	42.95M	-130.01M	-19.66M	-1.6278
VRTX Vertex Pharmaceuticals Inc	514.56	132.08B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	793.26	83.15B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	984.04	62.71B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	136.62	54.14B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	203.35	44.51B	742.00K	-1.37B	-1.07B	-7.0731

Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-12-19	Downgrade	Wells Fargo	Overweight → Equal Weight
2024-02-15	Iniziato	Wedbush	Outperform
2023-01-03	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2022-10-13	Iniziato	UBS	Buy
2022-08-15	Iniziato	Jefferies	Buy
2022-04-28	Iniziato	Credit Suisse	Neutral
2022-02-10	Iniziato	Wells Fargo	Equal Weight
2021-10-14	Iniziato	SVB Leerink	Mkt Perform

Mostra tutto

Monte Rosa Therapeutics Inc Borsa (GLUE) Ultime notizie

01:40 AM

Monte Rosa Therapeutics at Wells Fargo: pipeline gains and long cash runway - Investing.com Canada

01:40 AM

04:46 AM

Wellington Management Group LLP Buys 78,635 Shares of Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat

04:46 AM

Sep 09, 2026

Monte Rosa Therapeutics (NASDAQ:GLUE) Earns "Outperform" Rating from Wedbush - MarketBeat

Sep 09, 2026

Sep 08, 2026

LifeSci Capital Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating - Moomoo

Sep 08, 2026

Monte Rosa Earns $50M Milestone Payment as Novartis Starts Phase 2 Trial - Minichart

Sep 08, 2026

Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 - Investing News Network

Sep 08, 2026

A $50 million payment is coming to Monte Rosa as Novartis starts a Sjögren’s trial - Stock Titan

Sep 08, 2026

Monte Rosa Announces $50M Milestone as Novartis Starts Phase 2 for MRT-6160 in Sjögren’s - TradingView

Sep 08, 2026

Sep 07, 2026

How Investors Are Reacting To Monte Rosa Therapeutics (GLUE) Advancing MRT-2359 Into Phase 2 Prostate Cancer Trial - webull.com

Sep 07, 2026

Sep 06, 2026

Trading Systems Reacting to (GLUE) Volatility - Stock Traders Daily

Sep 06, 2026

Sep 05, 2026

Bank of New York Mellon Corp Acquires New Shares in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat

Sep 05, 2026

Sep 04, 2026

GLUE News | MONTE ROSA THERAPEUTICS INC (NASDAQ:GLUE) - ChartMill

Sep 04, 2026

Sep 03, 2026

Monte Rosa Therapeutics: High-Stakes Drug Pipeline Balanced By A Fortress Balance Sheet - Seeking Alpha

Sep 03, 2026